Clinical trialObservationalWithdrawn
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
- Outcome
- Stopped earlyAbandoned prior to launch. (Other)
- Phase
- Observational
- Status
- Withdrawn
- Study type
- Observational
- Planned start
- November 2024
- Planned end
- May 2030
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Best overall response (BOR)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 25 November 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.